165 related articles for article (PubMed ID: 1385561)
1. Phytanic acid alpha-oxidation: accumulation of 2-hydroxyphytanic acid and absence of 2-oxophytanic acid in plasma from patients with peroxisomal disorders.
ten Brink HJ; Schor DS; Kok RM; Poll-The BT; Wanders RJ; Jakobs C
J Lipid Res; 1992 Oct; 33(10):1449-57. PubMed ID: 1385561
[TBL] [Abstract][Full Text] [Related]
2. Phytanic acid oxidation: normal activation and transport yet defective alpha-hydroxylation of phytanic acid in peroxisomes from Refsum disease and rhizomelic chondrodysplasia punctata.
Pahan K; Khan M; Singh I
J Lipid Res; 1996 May; 37(5):1137-43. PubMed ID: 8725164
[TBL] [Abstract][Full Text] [Related]
3. Phytanic acid alpha-oxidation in peroxisomal disorders: studies in cultured human fibroblasts.
Verhoeven NM; Schor DS; Roe CR; Wanders RJ; Jakobs C
Biochim Biophys Acta; 1997 Oct; 1361(3):281-6. PubMed ID: 9375802
[TBL] [Abstract][Full Text] [Related]
4. In vivo study of phytanic acid alpha-oxidation in classic Refsum's disease and chondrodysplasia punctata.
ten Brink HJ; Schor DS; Kok RM; Stellaard F; Kneer J; Poll-The BT; Saudubray JM; Jakobs C
Pediatr Res; 1992 Nov; 32(5):566-70. PubMed ID: 1282700
[TBL] [Abstract][Full Text] [Related]
5. Studies on the oxidation of phytanic acid and pristanic acid in human fibroblasts by acylcarnitine analysis.
Verhoeven NM; Jakobs C; ten Brink HJ; Wanders RJ; Roe CR
J Inherit Metab Dis; 1998 Oct; 21(7):753-60. PubMed ID: 9819705
[TBL] [Abstract][Full Text] [Related]
6. Accumulation of pristanic acid (2, 6, 10, 14 tetramethylpentadecanoic acid) in the plasma of patients with generalised peroxisomal dysfunction.
Poulos A; Sharp P; Fellenberg AJ; Johnson DW
Eur J Pediatr; 1988 Feb; 147(2):143-7. PubMed ID: 2452737
[TBL] [Abstract][Full Text] [Related]
7. Pristanic acid and phytanic acid in plasma from patients with peroxisomal disorders: stable isotope dilution analysis with electron capture negative ion mass fragmentography.
ten Brink HJ; Stellaard F; van den Heuvel CM; Kok RM; Schor DS; Wanders RJ; Jakobs C
J Lipid Res; 1992 Jan; 33(1):41-7. PubMed ID: 1372637
[TBL] [Abstract][Full Text] [Related]
8. Stereochemistry of the peroxisomal branched-chain fatty acid alpha- and beta-oxidation systems in patients suffering from different peroxisomal disorders.
Ferdinandusse S; Rusch H; van Lint AE; Dacremont G; Wanders RJ; Vreken P
J Lipid Res; 2002 Mar; 43(3):438-44. PubMed ID: 11893780
[TBL] [Abstract][Full Text] [Related]
9. Evidence against alpha-hydroxyphytanic acid as an intermediate in the metabolism of phytanic acid.
Skjeldal OH; Stokke O
Scand J Clin Lab Invest; 1988 Feb; 48(1):97-102. PubMed ID: 2464193
[TBL] [Abstract][Full Text] [Related]
10. Clinical and biochemical heterogeneity in conditions with phytanic acid accumulation.
Skjeldal OH; Stokke O; Refsum S; Norseth J; Petit H
J Neurol Sci; 1987 Jan; 77(1):87-96. PubMed ID: 2433405
[TBL] [Abstract][Full Text] [Related]
11. Phytanic acid alpha-oxidation and complementation analysis of classical Refsum and peroxisomal disorders.
Poll-The BT; Skjeldal OH; Stokke O; Poulos A; Demaugre F; Saudubray JM
Hum Genet; 1989 Jan; 81(2):175-81. PubMed ID: 2463966
[TBL] [Abstract][Full Text] [Related]
12. The metabolism of phytanic acid and pristanic acid in man: a review.
Verhoeven NM; Wanders RJ; Poll-The BT; Saudubray JM; Jakobs C
J Inherit Metab Dis; 1998 Oct; 21(7):697-728. PubMed ID: 9819701
[TBL] [Abstract][Full Text] [Related]
13. Disorders related to the metabolism of phytanic acid.
Stokke O; Skjeldal OH; Høie K
Scand J Clin Lab Invest Suppl; 1986; 184():3-10. PubMed ID: 2438746
[TBL] [Abstract][Full Text] [Related]
14. [Peroxisomal neurologic diseases and Refsum disease: very long chain fatty acids and phytanic acid as diagnostic markers].
Molzer B; Stöckler S; Bernheimer H
Wien Klin Wochenschr; 1992; 104(21):665-70. PubMed ID: 1282286
[TBL] [Abstract][Full Text] [Related]
15. Identification and diagnostic value of phytanoyl- and pristanoyl-carnitine in plasma from patients with peroxisomal disorders.
Herzog K; van Lenthe H; Wanders RJA; Vaz FM; Waterham HR; Ferdinandusse S
Mol Genet Metab; 2017 Jul; 121(3):279-282. PubMed ID: 28566232
[TBL] [Abstract][Full Text] [Related]
16. Localization of the oxidative defect in phytanic acid degradation in patients with Refsum's disease.
Mize CE; Herndon JH; Blass JP; Milne GW; Follansbee C; Laudat P; Steinberg D
J Clin Invest; 1969 Jun; 48(6):1033-40. PubMed ID: 4181594
[TBL] [Abstract][Full Text] [Related]
17. Peroxisomes, Refsum's disease and the alpha- and omega-oxidation of phytanic acid.
Wanders RJ; Komen JC
Biochem Soc Trans; 2007 Nov; 35(Pt 5):865-9. PubMed ID: 17956234
[TBL] [Abstract][Full Text] [Related]
18. Phytanic acid alpha-oxidation in rat liver peroxisomes. Production of alpha-hydroxyphytanoyl-CoA and formate is enhanced by dioxygenase cofactors.
Mihalik SJ; Rainville AM; Watkins PA
Eur J Biochem; 1995 Sep; 232(2):545-51. PubMed ID: 7556205
[TBL] [Abstract][Full Text] [Related]
19. Refsum's disease: a peroxisomal disorder affecting phytanic acid alpha-oxidation.
Wierzbicki AS; Lloyd MD; Schofield CJ; Feher MD; Gibberd FB
J Neurochem; 2002 Mar; 80(5):727-35. PubMed ID: 11948235
[TBL] [Abstract][Full Text] [Related]
20. The enzymatic and mass spectrometric identification of 2-oxophytanic acid, a product of the peroxisomal oxidation of l-2-hydroxyphytanic acid.
Vamecq J; Draye JP
Biomed Environ Mass Spectrom; 1988 Mar; 15(6):345-51. PubMed ID: 3288289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
